Provided by Tiger Trade Technology Pte. Ltd.

Lexeo Therapeutics

3.38
-0.0400-1.17%
Volume:3.05M
Turnover:10.38M
Market Cap:277.32M
PE:-2.95
High:3.59
Open:3.44
Low:3.28
Close:3.42
52wk High:10.99
52wk Low:2.98
Shares:82.05M
Float Shares:51.23M
Volume Ratio:1.20
T/O Rate:5.96%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1457
EPS(LYR):-1.8634
ROE:-46.76%
ROA:-27.59%
PB:1.18
PE(LYR):-1.81

Loading ...

Have Insiders Sold Lexeo Therapeutics Shares Recently?

Simply Wall St.
·
Jul 03

Top Brass at Lexeo Therapeutics Quietly Unload a Chunk of Company Stock

TIPRANKS
·
Jul 02

Lexeo Therapeutics Holds Virtual Annual Stockholder Meeting

Reuters
·
Jun 30

Lexeo Therapeutics is Maintained at Overweight by JP Morgan

Dow Jones
·
Jun 25

Lexeo Therapeutics price target lowered to $9 from $12 at JPMorgan

TIPRANKS
·
Jun 25

Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia

GlobeNewswire
·
Jun 18

BUZZ-U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex

Reuters
·
Jun 16

Lexeo Therapeutics Finalizes Study Design for Friedreich Ataxia Gene Therapy

MT Newswires Live
·
Jun 15

Lexeo finalizes SUNRISE-FA 2 pivotal trial protocol, statistical analysis plan

TIPRANKS
·
Jun 15

Lexeo Therapeutics releases corporate presentation on cardiac gene therapy platform for inherited heart disease

Reuters
·
Jun 15

Lexeo finalizes SUNRISE-FA 2 pivotal trial design for LX2006 in Friedreich ataxia cardiomyopathy

Reuters
·
Jun 15

Lexeo Therapeutics - Topline Data Readout Expected in H2 2027; Bla Submission in H1 2028

THOMSON REUTERS
·
Jun 15

Lexeo Therapeutics - Sunrise-Fa 2 Initiation on Track for Q2 2026; First Patient Expected by End of June

THOMSON REUTERS
·
Jun 15

Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for Lx2006 Gene Therapy in Friedreich Ataxia

THOMSON REUTERS
·
Jun 15

Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia

GlobeNewswire
·
Jun 15

Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

GlobeNewswire
·
May 19

Lexeo Therapeutics, Inc. (LXEO) Gets a Buy from RBC Capital

TIPRANKS
·
May 12

Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Lexeo Therapeutics, Inc. (LXEO)

TIPRANKS
·
May 12

Lexeo Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
May 12

Lexeo Therapeutics reports Q1 EPS (25c), consensus (30c)

TIPRANKS
·
May 11